Results 151 to 160 of about 6,372 (199)

Modeling Malaria Rebound After Mass Drug Administration: The Role of Importation and Waning Immunity in Lake Victoria, Kenya

Wachuka R, Mwalili S, Kulei W, Mbugua PM, Omondi P, Kagaya W, Langat AK, Kaneko A, Kanoi BN, Gitaka J.   +9 more
europepmc   +1 more source

Identification of an isomer impurity in piperaquine drug substance

Journal of Chromatography A, 2006
A significant contaminant of the antimalarial drug piperaquine (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]propane) has been identified using liquid chromatography-mass spectrometry (LC-MS) and 2D NMR spectroscopy (1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC).
Nicholas White, Diego Carnevale
exaly   +4 more sources

Efficacy of dihydroartemisinin/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaoundé, Cameroon

Journal of Antimicrobial Chemotherapy, 2021
International audienceBackground: Dihydroartemisinin/piperaquine is increasingly used for the treatment of uncomplicated Plasmodium falciparum malaria in Africa.
Isabelle Morlais, Antoine Berry, Melissa Mairet-Khedim   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Piperaquine

Drugs, 2005
Piperaquine is a bisquinoline antimalarial drug that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria, but ...
Timothy M E, Davis, Te-Yu, Hung, Ing-Kye, Sim, Harin A, Karunajeewa, Kenneth F, Ilett   +4 more
openaire   +2 more sources

Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy [PDF]

Antimicrobial Agents and Chemotherapy, 2021
Dihydroartemisinin-piperaquine (DP) is a long-acting artemisinin combination treatment that provides effective chemoprevention and has been proposed as an alternative antimalarial drug for intermittent preventive therapy in pregnancy (IPTp).
Julie Gutman, Din Syafruddin, Simon Kariuki   +2 more
exaly   +2 more sources

Infectivity and Screening of Anti-piperaquine Genes in Mice Infected with Piperaquine-Sensitive and Piperaquine-Resistant Plasmodium berghei

Acta Parasitologica, 2019
Piperaquine (PQ) is one of the major components of artemisinin-based combination therapy for malaria. However, the mechanism of PQ resistance has remained unclear.In this study, we infected mice with PQ-resistant Plasmodium berghei ANKA strain line (PbPQR) or PQ-sensitive P.
Guohui, Yi, Limin, Zhou, Zhanhong, Ye, Xianxi, Huang, Fangli, Lu, Hong, Guo   +5 more
openaire   +2 more sources

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers [PDF]

British Journal of Clinical Pharmacology, 2017
AIMS: The aims of the presented study were to evaluate the pharmacokinetic properties of dihydroartemisinin and piperaquine, potential drug-drug interactions with concomitant primaquine treatment, and piperaquine effects on the electrocardiogram in ...
Podjanee Jittamala, Nicholas White, Richard M Höglund   +2 more
exaly   +2 more sources

Toxicology and pharmacokinetics of piperaquine in mice

Toxicology, 2008
Pharmacokinetic and toxicological data for piperaquine (PQ) - a bisquinoline antimalarial drug - are limited, despite strong evidence of clinical efficacy. Our aim was to conduct a detailed toxicological investigation of PQ in Swiss mice. The study comprised three phases: (i) oral PQ phosphate (PQP) at doses ranging from 0 to 600 mg/(kg day) for 5 days.
Batty, Kevin, Moore, Brioni, Stirling, V., Ilett, K., Page-Sharp, M., Shilkin, K., Mueller, I., Karunajeewa, H., Davis, Timothy   +8 more
openaire   +3 more sources

Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants [PDF]

Journal of Infectious Diseases, 2013
BACKGROUND: Although dihydroartemisinin-piperaquine (DP) is used primarily in children, pharmacokinetic/pharmacodynamic (PK/PD) data on DP use in young children are lacking.
Darren Creek, Francesca Aweeka, François Nosten   +2 more
exaly   +2 more sources

Piperaquine phosphate: Reproduction studies

Reproductive Toxicology, 2012
In embryofetal studies in rat and rabbit Piperaquine phosphate (PQP) was not teratogenic at the maximal tolerated dose, even in presence of fetal exposure. In peri- post-natal study in rat, PQP did not interfere with the course of delivery at the dose of 5 mg/kg/day (treatment Gestation Day(GD)6-Lactation Day(LD)21) as well as up to the dose of 20 mg ...
Monica, Longo, Silvia, Pace, Monica, Messina, Laura, Ferraris, Marco, Brughera, David, Ubben, Guy, Mazuè   +6 more
openaire   +2 more sources